EcoDrugPlus

Beta-3 Adrenergic Receptor

Ensembl ID : ENSAMXG00000020601
Gene Symbol: LOC103028061
3 Cross references
146 Possible Orthologues:

Beta-Secretase 1

Ensembl ID : ENSAMXG00000009844
Gene Symbol: BACE1
3 Cross references
221 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSAMXG00000038266
Gene Symbol: BDKRB2
2 Cross references
151 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSAMXG00000026334
Gene Symbol: BDKRB2
2 Cross references
287 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSAMXG00000024900
Gene Symbol: BDKRB2
3 Cross references
160 Possible Orthologues:

Bromodomain-Containing Protein 4b-Like

Ensembl ID : ENSAMXG00000004573
Gene Symbol: LOC103037777
2 Cross references
193 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4b-Like

Ensembl ID : ENSAMXG00000032214
Gene Symbol: LOC103042361
2 Cross references
180 Possible Orthologues:

Cgmp-Specific 3',5'-Cyclic Phosphodiesterase-Like

Ensembl ID : ENSAMXG00000017789
Gene Symbol: LOC103024399
3 Cross references
209 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSAMXG00000007676
Gene Symbol: CACNA1C
1 Cross references
215 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1d Subunit, A

Ensembl ID : ENSAMXG00000007177
Gene Symbol: CACNA1DA
1 Cross references
213 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1f Subunit

Ensembl ID : ENSAMXG00000007496
Gene Symbol: CACNA1FB
1 Cross references
177 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit, A

Ensembl ID : ENSAMXG00000008958
Gene Symbol: CACNA1SA
1 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).